ArriVent BioPharma, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

AVBP$13.49-4.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Cash Flows

(in thousands)


· · Three Months Ended
· · March 31,
· · 2026 · · 2025
Cash flows from operating activities: · · · ·
Net loss	$(43,320)	$(64,387)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	5,485	2,271
Amortization/Accretion of bond discounts/premiums	(559)	—
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,561)	(1,591)
Other assets	37	—
Accounts payable	2,807	582
Accrued expenses	(3,828)	(4,879)
Operating lease liabilities	47	(4)
Net cash used in operating activities	(41,892)	(68,008)
Cash flows from investing activities:
Purchase of short-term and long-term investments	(64,383)	(9,817)
Sales and maturities of short-term and long-term investments	67,965	46,638
Net cash used in investing activities	3,582	36,821
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs	54,724	6,516
Proceeds from the exercise of stock options	149	293
Payment of deferred financing costs	—	(50)
Net cash provided by financing activities	54,873	6,759

Net increase (decrease) in cash and cash equivalents	16,563	(24,428)
Cash and cash equivalents at beginning of the year	45,540	74,293
Cash and cash equivalents at end of the year	$62,103	$49,865

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.